A 24-Week, Multi-Center, Randomized, Open-Label Clinical Trial Comparing the Effects of Xuezhikang and Atorvastatin on Glucose Metabolism in Patients with Dyslipidemia and Prediabetes (XTREME Study): Design of the Study Protocol
Background: Statins, a first-line therapeutic option for atherosclerotic cardiovascular disease (ASCVD), have prompted concerns regarding dysglycemia and diabetes, thus posing a dilemma in treating patients with prediabetes. Xuezhikang (XZK) decreases blood cholesterol levels without affecting gluc...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Compuscript Ltd
2024-01-01
|
| Series: | Cardiovascular Innovations and Applications |
| Online Access: | https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2024.0010 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|